Shwachman-Diamond Syndrome (SDS) is a rare multisystem disorder characterized by exocrine pancreatic insufficiency, bone marrow dysfunction, and metaphyseal chondrodysplasia. Recent studies show that mutations of SBDS, a gene of unknown function, are present in the majority of patients with SDS. In the present study, we show that most, but not all, patients classified based on rigorous clinical criteria as having SDS had compound heterozygous mutations of SBDS. Full length SBDS protein was not detected in leukocytes of SDS patients with the most common SBDS mutations, consistent with a loss-of-function mechanism. In contrast, SBDS protein was expressed at normal levels in SDS patients without SBDS mutations. These data confirm the absence of SBDS mutations in this subgroup of patients and suggest that SDS is a genetically heterogeneous disorder. The presence (or absence) of SBDS mutations may define subgroups of patients with SDS that share distinct clinical features or natural history.
INTRODUCTION
Shwachman-Diamond Syndrome (SDS) is a rare multisystem disorder characterized by exocrine pancreatic insufficiency, bone marrow dysfunction, and metaphyseal chondrodysplasia. [1] [2] [3] [4] [5] SDS is the second most common cause of congenital exocrine pancreatic insufficiency after cystic fibrosis. Bone marrow dysfunction is present in nearly all patients with SDS. [3] [4] [5] [6] In the largest published series (88 patients), chronic or intermittent neutropenia was present in 97%. 5 Anemia and thrombocytopenia were present in more than a third of patients. Patients with SDS have a marked propensity to develop myelodysplasia or acute myeloid leukemia. [6] [7] [8] SDS is inherited in an autosomal recessive fashion. 9 Recently, Boocock et al.
reported that compound heterozygous mutations of the SBDS (Shwachman-BodianDiamond syndrome) gene on chromosome 7 were present in the majority of patients with SDS. 10 Most of these mutations resulted from gene conversion with a neighboring pseudogene (SBDSP). Similar data were reported in a smaller series of patients of Japanese ancestry. 11 Most of the SBDS mutations are predicted to truncate a substantial portion of the SBDS protein, suggesting that they act in a loss-of-function manner.
Herein, we show that most, but not all, patients classified prospectively based on clinical criteria as having probable SDS had SBDS gene mutations. Moreover, a strong correlation between SBDS genotype and expression of full length SBDS protein was observed.
MATERIAL AND METHODS
Human subjects. 33 families who attended the Second International Conference on Shwachman-Diamond Syndrome in St. Louis in 1999 were invited to participate in a study to elucidate the genetic basis of SDS. After obtaining informed consent, a thorough history, physical examination, review of medical records, and selected laboratory testing were performed. In addition, genomic DNA was extracted from peripheral blood leukocytes using standard protocols. The diagnosis of SDS was based on the presence of the following two criteria, 12 bone marrow failure (neutrophils < 1500 x 10 6 /l, hemoglobin < 10 g/dl, or platelets < 150 x 10 9 /l) or exocrine pancreatic insufficiency (serum trypsinogen < 16.7 µg/l, abnormal pancreatic stimulation test, low fat soluble vitamin levels, or abnormal 72-hour fecal fat study together with a characteristic pancreatic abnormality in an imaging study). A diagnosis of SDS was considered probable when both criteria were documented in the medical record or by the 
RESULTS AND DISCUSSION
Genomic DNA suitable for sequencing was available for 29 of the 33 families. Clinical characteristics of the probands in these families at the time of their participation in this study are shown in table 1. Based on clinical criteria outlined in Methods, 18 of these families were classified as having one or more affected individuals with probable SDS, 6 with possible SDS, and 3 were judged not to have SDS. In 2 families, insufficient data was available to classify the probands ("unclassified").
Compound heterozygous mutations of the SBDS gene were detected in the majority of patients with probable or possible SDS (table 1) . In agreement with previous reports, the 258+2T>C and 183-184TA>CT mutations were the most common. 10, 11 The 258+2T>C mutation results in the disruption of the donor splice site of intron 2 and the use of a cryptic splice donor site a position 251-252. The resulting abnormally spliced mRNA results in a frameshift and the premature truncation of the 250 amino acid SBDS Age at time of entry into registry and laboratory evaluation. 2 The absolute neutrophil count (ANC) for patients receiving is indicated by "(G)". For personal use only. on October 22, 2017. by guest www.bloodjournal.org From protein at amino acid 84. 10 A single patient had a 258+1G>C mutation that results in a similar splicing defect. The 183-184TA>CT mutation introduces a premature stop codon resulting in the truncation of the SBDS protein at amino acid 62. Point mutations resulting in single amino acid substitutions were detected in two families. The 505C>T mutation has been reported previously and results in a cysteine for arginine substitution at amino acid 169. 10 The 652C>T mutation is novel and generates a premature stop codon at amino acid 218. None of these mutations were detected in 48 healthy controls.
In 18% (5 of 28) of patients classified with probable or possible SDS, SBDS mutations were not detected (table 1) . Likewise, no SBDS mutations were detected in 11% (17 of 158) 10 and 29% (2 of 7) 11 of previously studied patients with SDS. Since sequence analysis in all three studies was limited to exons, splice junctions, and the The relative densitometry signal for the SBDS band compared to the actin band is shown for lanes 9-13. Molecular size markers are indicated at the left in kDa. This data is representative of two independent experiments using the same protein extracts. 
